Already registered?
2
3

Latest shared news, insight and analysis for the global pharma community

Next steps in healthcare big data: what, why and how

Big data is at the very heart of the next major innovation wave in healthcare that has the potential to bring about productivity gains and increase cost efficiencies to the provider, facilitate innovation for suppliers, while improving patient outcomes. Clinica Medtech Intelligence, with the support of GE Healthcare, organized a roundtable discussion which brought together different stakeholders in the healthcare delivery chain to explore this subject discuss key issues such as the application of big data, information confidentiality, how to incentivize stakeholders to buy into the idea of healthcare big data and what controls there are if things go wrong. Click here ...


Webinar: Making the Most Out of Your Mature Brands

We invite you to Join Europe’s most authoritative expert on lifecycle management (LCM), Dr. Neal Hansen, as he reveals top tricks and tips to help you get more out of your mature brands. Please click here to register. Benefits of joining the webinar include:  Understand why you need to make the most out of your mature brand portfolio. Hear about the evolving role of Established Brand Teams and how they are being transformed for success. Learn about tactics you can use to optimize the performance of your portfolio. Gain insight from Datamonitor Consulting’s delivery of LCM solutions across the pharmaceutical industry. The session will comprise a 40 ...


Whitepaper: Basejumping for Pharma

If there is one fact that even the most casual observer of the pharma industry is aware of, it is that there is a patent cliff, and we are in the process of falling off it! Latest numbers would suggest that brands generating more than $150bn in global sales in 2010 will lose primary patent protection in at least one major market by 2015, building on the $ in 2005 branded revenue that has faced patent expiry over the last five years. While this obviously represents a significant amount of money for the pharma industry, it is the concurrent challenges in ...


Webinar: Surviving Patent Expiry – Basejumping for Pharma

Join Europe’s most authoritative expert on lifecycle management, Dr. Neal Hansen, as he reveals top tricks and tips to help you manage your brands through patent expiry. Reserve Your Place Benefits of joining the webinar include: Getting an insight into what happens at patent expiry, including what drives and shapes generic erosion. Learn about tactics you can use to optimize your brand performance. Hear how you can shape your organization to succeed at patent expiry. Gain insight from Datamonitor Consulting’s delivery of LCM solutions across the pharmaceutical industry. The session will comprise a 20 minute presentation followed by a Q&A session. If you have any critical questions you would like to ...


Analyst presentation on latest biosimilars analysis

Biosimilars are more established in the EU than the US and Japan, with a total of 13 ‘first wave’ product approvals, but the prospects for complex products such as monoclonal antibodies remain unclear. A key event will be the review of Celltrion/Hospira’s version of Remicade (infliximab) - submitted to the EMA in April 2014. Its chances of success have improved following approval in Korea as Remsima on July 2012. View our analysts presenting key findings from our extended database of 88 marketed and development stage EU biosimilars.  


GSK launches first dose-counting inhaler in India, but domestic competition on the way

GlaxoSmithKline Pharmaceuticals has introduced in India an enhanced version of a metered dose inhaler (MDI) with a dose counter, the first of its kind in the country, although a clutch of domestic firms are also believed to be working on their own versions of dose counters. While MDIs, which have been available for around five decades, are generally regarded as the preferred method of delivery for several drugs to treat obstructive airway diseases such as asthma, emphysema, and chronic bronchitis, they offered no practical way for patients to track the remaining numbers of doses or amount of medication. GSK said that its ...


$66m PE investment in Indian diagnostics chain amid sectoral promise

Indian diagnostics chain Super Religare Laboratories (SRL) is set to receive a capital injection of Rs3.70bn ($66.3m) from private equity fund, NYLIM Jacob Ballas India Fund, and the World Bank arm, International Finance Corporation (IFC). The move is seen as indicative of the high potential of the diagnostics segment despite the general gloom on the economic front. This deal marks the third round of private equity investment in SRL, after Avigo Capital Partners and Sabre Partners invested Rs1.50bn in the firm last year. Fortis Healthcare, a leading healthcare chain in the Asia-Pacific region and SRL's parent company, said that NYLIM Jacob Ballas ...


Models of partnership between the pharmaceutical and diagnostics industries around companion diagnostics for cancer and beyond

Models of partnership between the pharmaceutical and diagnostics industries around companion diagnostics for cancer and beyond Christian Ensinger MD Expert Opinion on Medical Diagnostics, March 2011, Vol. 5, No. 2 , Pages 91-94 (doi:10.1517/17530059.2011.552497) An increase of targeted anticancer therapies has led to the beginning of a new era of cancer treatment, partly by replacing classical chemotherapies, partly supplementing these. Whereas for some substances only clinical experiences are relevant for treatment decisions, for some major cancer groups predictive markers are known that indicate probable tumor responses. To identify the latter, a need for companion diagnostics is given, often already existing as successful ...


Compatibility testing of two types of pen needles with a range of injection pens for diabetes medication

Compatibility testing of two types of pen needles with a range of injection pens for diabetes medication Peter Buus, Søren Kruse Lilleøre, Kirsten Larsen Current Medical Research & Opinion March 2011, Vol. 27, No. 3 , Pages 589-592 (doi:10.1185/03007995.2010.547574) Compatibility of two types of needles with a variety of durable and prefilled injection pens for diabetes medication was tested by attaching the needles according to ISO 11608-2 and verifying penetration into the cartridge using air shots and two-dimensional X-rays. NovoFine* and NovoFine Autocover† attached correctly to 20 and 19 out of 21 pen types, respectively. Neither needle type attached to Diapen 3.1/3.2, ...


Companion Diagnostics: A Rocky Road Ahead?

Gabrielle Gessner, Citeline Senior Analyst, Infectious & Genitourinary Diseases Companion diagnostic pairs are emerging as the new face of personalized medicine, allowing treatment decisions to be specifically tailored to each patient.  However, development of the drug/diagnostic pair poses increasing challenges in clinical development as regulatory policy scrambles to accommodate this new field. Companion diagnostics are drug and diagnostic pairs where safe and effective use of the drug depends on a specific diagnostic test, which can be predictive or monitoring.  Predictive companion diagnostics determine which patients will respond to treatment,  the appropriate dose, or those at risk for specific adverse events.  Monitoring companion ...